Home › Funds › Merck & Co., Inc. › ALEC
Merck & Co., Inc. position in ALEC
ALECTOR INC · Health Care
Merck & Co., Inc. reported holding 3,545,719 shares of ALEC (ALECTOR INC) in its Q3 2026 13F filing — a position valued at US$6.6M, representing 0.80% of its reported portfolio and ranking #7 among its reported holdings. Merck & Co., Inc. has disclosed ALEC holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Merck & Co., Inc.'s ALEC position evolved
Merck & Co., Inc. first disclosed a stake in ALEC in Q4 2024 at 3,545,719 shares (US$6.7M). The position peaked in Q3 2025 at 3,545,719 shares, worth US$10.5M. Across 8 filings, Merck & Co., Inc. held the position steady without any share-count change. The most recent filing (Q3 2026) shows 3,545,719 shares valued at US$6.6M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 3.55M | $6.70M | New |
| Q1 2025 | 3.55M | $4.36M | Hold |
| Q2 2025 | 3.55M | $4.96M | Hold |
| Q3 2025 | 3.55M | $10.50M | Hold |
| Q4 2025 | 3.55M | $5.53M | Hold |
| Q1 2026 | 3.55M | $7.62M | Hold |
| Q2 2026 | 3.55M | $7.13M | Hold |
| Q3 2026 | 3.55M | $6.56M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALEC and 13F data
ALEC (ALECTOR INC) is a Health Care company. 27 other funds we track also report a position in ALEC — the largest reported positions include TCG Crossover Management, LLC (US$20.1M), Kynam Capital Management, LP (US$7.7M), Ikarian Capital, LLC (US$4.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALEC
- TCG Crossover Management, LLC 10.00M sh · $20.10M · Q2 2026
- Kynam Capital Management, LP 3.81M sh · $7.66M · Q2 2026
- Ikarian Capital, LLC 1.98M sh · $3.99M · Q2 2026
- Spruce Street Capital LP 2.10M sh · $3.89M · Q3 2026
- MEDICI CAPITAL LLC 1.65M sh · $3.06M · Q3 2026
- Euclidean Capital LLC 1.31M sh · $2.63M · Q2 2026
More on Merck & Co., Inc.
FAQ
How long has Merck & Co., Inc. held ALEC?
Merck & Co., Inc. has disclosed ALEC holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Merck & Co., Inc.'s current position in ALEC?
As of Q3 2026, Merck & Co., Inc. holds 3.55M shares of ALEC (ALECTOR INC), valued at $6.56M, representing 0.80% of its reported portfolio and ranking #7.
Has Merck & Co., Inc. been buying or selling ALEC?
In the latest 13F filing (Q3 2026), Merck & Co., Inc. held unchanged its position in ALEC. The position peaked in Q3 2025 at 3.55M shares.
Which other funds hold ALEC?
Other major institutional holders of ALEC include TCG Crossover Management, LLC, Kynam Capital Management, LP, Ikarian Capital, LLC, among 27 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.